1
|
Kittai AS, Allan JN, James D, Bridge H, Miranda M, Yong AS, Fam F, Roos J, Shetty V, Skarbnik AP, Davids MS. An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL. Blood Adv 2024:bloodadvances.2023012142. [PMID: 38598745 DOI: 10.1182/bloodadvances.2023012142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 03/28/2024] [Accepted: 03/30/2024] [Indexed: 04/12/2024] Open
Abstract
The efficacy and safety of acalabrutinib plus obinutuzumab and acalabrutinib monotherapy versus zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without del(17p) were compared using an unanchored matching-adjusted indirect comparison. Individual patient-level data (IPD) from ELEVATE-TN (acalabrutinib plus obinutuzumab, n = 162; acalabrutinib monotherapy, n = 163) were weighted to match published aggregate baseline data from SEQUOIA cohort 1, which excluded patients with del(17p) (zanubrutinib, n = 241), using variables that were prognostic/predictive of investigator-assessed progression-free survival (INV-PFS) in an exploratory Cox regression analysis of ELEVATE-TN. Post-matching, INV-PFS was longer with acalabrutinib plus obinutuzumab (hazard ratio [HR]: 0.41; 95% CI: 0.23-0.74) and comparable with acalabrutinib monotherapy (HR: 0.91; 95% CI: 0.53-1.56) versus zanubrutinib. Acalabrutinib monotherapy had significantly lower odds of any grade hypertension versus zanubrutinib (OR: 0.44, 95% CI: 0.20-0.99), while acalabrutinib plus obinutuzumab had significantly higher odds of neutropenia (odds ratio [OR]: 2.19; 95% CI: 1.33-3.60) and arthralgia (OR: 2.33; 95% CI: 1.37-3.96) versus zanubrutinib. No other significant differences in safety were observed. In summary, compared with zanubrutinib, acalabrutinib plus obinutuzumab had longer INV-PFS with increased odds of neutropenia and arthralgia, whereas acalabrutinib monotherapy had similar INV-PFS with lower odds of any grade hypertension.
Collapse
Affiliation(s)
- Adam S Kittai
- The Ohio State University, Columbus, Ohio, United States
| | - John N Allan
- Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, United States
| | - Dan James
- Polaris Biostatistics Ltd, Edinburgh, United Kingdom
| | | | | | - Alan Sm Yong
- AstraZeneca, Gaithersburg, Maryland, United States
| | - Fady Fam
- AstraZeneca, Cambridge, United Kingdom
| | - Jack Roos
- AstraZeneca, Gaithersburg, Maryland, United States
| | | | | | - Matthew S Davids
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
| |
Collapse
|
3
|
Fam F, Palleschi V, Singh DP, Vaselli M. Derivation of the critical angle for Mach reflection for strong shock waves. Phys Rev A 1992; 45:6130-6132. [PMID: 9907718 DOI: 10.1103/physreva.45.6130] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|